A comparison of poly(methyl methacrylate) and silorane-based cements as carriers for local doxorubicin delivery Authors: Grahmm A. Funk, Elizabeth M. Menuey, Zachary D. Denton, Dalan M. Pittz, Alejandro Parrales, Tomoo Iwakuma, Kathleen V. Kilway, Terence E. McIff Published: 2025 ABSTRACT Orthopedic osteosarcomas and metastatic lesions can be difficult to treat with systemically delivered chemotherapy agents alone. Following removal of the primary tumor, implantation of cement to fill the lesion is often done to stabilize weight-bearing bones. One of the commonly used treatments to address osteosarcoma is systemic delivery of doxorubicin. Therefore, research on the incorporation and release of efficacious doxorubicin for local delivery from cement is important. Poly(methyl methacrylate) (PMMA)-based bone cements are the gold standard in orthopedics but have inherent disadvantages. Efforts to overcome some of these deficiencies led to the development of a novel silorane-based biomaterial (SBB). This work evaluated the ability of both PMMA and SBB to incorporate and release efficacious doxorubicin. PMMA-released doxorubicin showed reduced chemotherapeutic efficacy in vitro. The mechanical properties of PMMA were reduced from controls upon doxorubicin incorporation, likely stemming from doxorubicin inhibition of PMMA radical polymerization. SBB properties were not affected by doxorubicin incorporation and SBB eluted doxorubicin was fully efficacious in vitro compared to doxorubicin controls. These results indicate a likely inhibitory interaction between PMMA and doxorubicin, which affects both the strength of PMMA and the efficacy of doxorubicin. Further, this work illustrates SBB as a potential biomaterial alternative for traditional acrylics for medical biomaterial applications where load-bearing strength alongside drug delivery are key factors. Introduction Primary and secondary malignant bone lesions affect many Americans each year resulting in substantial mortality and morbidity. Complications include severe pain, hypercalcemia, and risk of bone fracture secondary to decalcification [1, 2]. The American Cancer Society estimates the incidence of primary bone sarcomas including osteosarcoma, chondrosarcoma, and Ewing sarcoma are rare at around 3,610 per year in the US [3]. Metastatic bone lesions, however, occur at a much higher rate and are found to be present in 4.8% of all solid tumor cancer patients at one year and in 8.4% of these patients at ten years [4]. The number of new cases of metastatic bone disease is estimated to be as high as 400,000 annually in the US [3, 5, 6]. Treatment of primary sarcomas and metastatic bone lesions is often multimodal involving systemically administered chemotherapy agents, surgery, and frequently, radiation therapy. Some of the most common adjuvant treatment regimens for osteosarcoma and metastatic lesions include systemic administration of chemotherapy agents such as doxorubicin, a very effective anthracycline [7]. Unfortunately, doxorubicin is associated with cellular toxicity during sustained systemic administration possibly due to the creation of reactive oxygen species (ROS) [8]. The most serious side effect of doxorubicin therapy is myocardial toxicity leading to dilated cardiomyopathy [9, 10]. In the hopes of reducing drug-induced toxicity, researchers have been identifying new ways of selectively targeting the region of interest or the tumor itself by means of drug encapsulation and local delivery methods [11, 12]. Bone cement is an important tool in the surgical arsenal against bone breakage and pain. Solitary or oligometastatic lesions are often treated by resection or using a percutaneous procedure of ablation and cement injection [6]. Osteoplasty or cementoplasty is sometimes done to strengthen post-surgical metastatic lesions and reduce pain by injecting bone cement into the weakened bone areas [13]. For large resections, both prophylactic and post-surgical reconstruction is done to stabilize the tumor site using metallic implants [14, 15]. Bone cement is frequently used to reinforce implant constructs and fill remaining voids providing needed structural support [6]. With bone cement often already present at the reconstruction site after tumor resection, it becomes a logical choice as a vehicle for local chemotherapy delivery. Locally targeted therapy can provide higher doses of drug to the lesion without the associated systemic toxicity. Researchers have previously investigated the potential for local chemotherapy delivery from orthopedic cements with drugs such as cisplatin, doxycycline, and methotrexate [16, 17], but doxorubicin delivery remains understudied. Poly(methyl methacrylate) (PMMA) bone cements are the industry standard in orthopedic surgery for implant anchoring and the filling of defects and voids left after bone resection. PMMA cements are routinely loaded with antibiotics both prophylactically and therapeutically and have been shown to release incorporated drugs for up to two weeks [18, 19]. However, PMMA bone cements undergo radical polymerization and are chemically incompatible with certain antibiotics. For example, rifampin, an antibiotic used for biofilm prevention and treatment, has been shown to inhibit PMMA polymerization and alter the material properties of the cement by way of radical scavenging through its hydroquinone moiety [20]. Doxorubicin also contains a hydroquinone moiety, warranting investigation into its potential compatibility with PMMA cements. Recognizing PMMA’s shortcomings, we previously developed a silorane-based biomaterial (SBB) for use as an orthopedic cement in both reconstructive surgery and drug delivery applications. This SBB cement undergoes non-exothermic polymerization, exhibits less curing shrinkage, has superior osteoconductivity, and has comparable drug elution rates to that of PMMA [19, 21, 22]. This study aimed to assess the potential of both PMMA and SBB to incorporate and release efficacious doxorubicin, while monitoring strength properties necessary for orthopedic weight-bearing applications. Experimental section/methods Silorane-based biomaterial & PMMA preparation The SBB is a 1:1 ratio of two monomers, 2,4,6,8-Tetrakis(2-(7-oxabicyclo[4.1.0]cheptan-3-yl)ethyl)-2,4,6,8-tetramethyl-1,3,5,7,2,4,6,8-tetraoxatetrasilocane (CYGEP) and bis[2-(3{7-oxabicyclo[4.1.0]heptyl})ethyl]methylphenyl silane (PHEPSI) (Fig. 1). They were synthesized and purified in-house as previously described [22]. Purity was ensured to be > 95.8% by using proton nuclear magnetic resonance (1H NMR) spectroscopy. The samples were combined with the initiation system and DY5 (yttria alumino-silicate; 15.0 wt% Y203, 5.0 wt% AI2O3, and 80 wt% Si02) modified 1TOSU (9,9-diethyl-l,5,7,l l- tetraoxaspiro[5.5]undecan-3-yl)methyl(trimethoxysilane) filler.Fig. 1The two monomers, CYGEP and PHEPSI that comprise the matrix of SBB. Medical grade doxorubicin was obtained from TCI America through Fischer Scientific. The PMMA specimens were fabricated using Depuy SmartSet MV PMMA (Depuy, USA). PMMA experimental and control groups were prepared by mixing the dry components (40 g) with and without the doxorubicin powder in a DePuy surgical mixing bowl until visual homogeneity was observed. Afterward, the liquid component (18.88 mL) was added to begin polymerization while the cement was mixed at 1 Hz at RT for 1.5 min using the commercially available mixing bowl apparatus (DePuy) The two monomers, CYGEP and PHEPSI that comprise the matrix of SBB. Medical grade doxorubicin was obtained from TCI America through Fischer Scientific. The PMMA specimens were fabricated using Depuy SmartSet MV PMMA (Depuy, USA). PMMA experimental and control groups were prepared by mixing the dry components (40 g) with and without the doxorubicin powder in a DePuy surgical mixing bowl until visual homogeneity was observed. Afterward, the liquid component (18.88 mL) was added to begin polymerization while the cement was mixed at 1 Hz at RT for 1.5 min using the commercially available mixing bowl apparatus (DePuy) As described in a previous publication, the SBB control and doxorubicin-laden samples were formulated by adding doxorubicin or not adding doxorubicin prior to polymerization [19]. To account for the difference in cement densities, the same amount of doxorubicin was added to each cement batch by volume rather than weight (0.88 v/v%). The final composition of the doxorubicin-incorporated SBB by weight was: Light-cured Sil-Mix (LCSM, 33.94%), Lamroux’s Catalyst (LMC, 0.40%), DY5-1TOSU (63.77%), and doxorubicin (0.46%). PMMA and SBB control and experimental group compositions are listed in Table 1.Table 1Experimental group compositions and additivesGroup NameCement TypeDoxorubicin (w/w%)Doxorubicin (v/v%)Pellet Density (g/mm3)PCONPMMA001.25×10-3PDOXPMMA0.680.881.23×10-3SCONSBB001.84×10-3SDOXSBB0.460.881.83×10-3 Table 1Experimental group compositions and additivesGroup NameCement TypeDoxorubicin (w/w%)Doxorubicin (v/v%)Pellet Density (g/mm3)PCONPMMA001.25×10-3PDOXPMMA0.680.881.23×10-3SCONSBB001.84×10-3SDOXSBB0.460.881.83×10-3 Experimental group compositions and additives Once the cements began curing, they were placed into custom polytetrafluoroethylene (PTFE) molds and allowed to cure for 1 h at 37 °C subsequently producing cylindrical specimens of dimensions 6 × 12 mm as per ASTM F451 [23]. All cement pellets were removed from the molds after curing, inspected for significant defects, and weighed. Visually defective samples and those with masses far from the mean were discarded to ensure low variability in specimen uniformity. Doxorubicin elution testing Control and doxorubicin-containing pellets from each cement type were each placed individually into 15 mL conical polypropylene test tubes. A 2.5 mL aliquot of elution media, 1x phosphate-buffered saline (PBS, Ricca, Arlington, TX), was added to each test tube to provide complete submersion of the cement cylinders. All specimens were stored at 37 °C in a static environment and in the absence of light to maintain doxorubicin stability. Elution collection was performed on all 10 specimens from each group every 24 h subsequently followed by the complete changeout of PBS after each collection. The concentration of doxorubicin in the eluate was measured using a Shimadzu 10 series HPLC (Shimadzu Corp., Kyoto, Japan) with a Hypersil GOLD C18 column (5 µm, 250 × 4.6 mm, Fisher Scientific, Hampton, NH, USA) at 36 °C with a UV detection wavelength of 233 nm. An isocratic mobile phase consisting of HPLC grade water and methanol (30:70 v/v%) adjusted to pH 3.0 with phosphoric acid (Fisher Scientific, USA) was used at a flow rate of 1.0 mL/min. A calibration curve was performed in triplicate to determine the doxorubicin concentration from the absorbance data. Doxorubicin efficacy testing To determine whether eluted doxorubicin from each type of cement retained chemotherapeutic efficacy, we assessed the viability of both MG-63 osteosarcoma cells and WI-38 fibroblasts (ATCC, USA). These cell types were selected due to their proximity and prevalence to the local elution of doxorubicin at an osteosarcoma resection site. For each test, MG63 (2000 cells/well) and WI38 (5000 cells/well) cells were seeded into a 96-well plate in DMEM culture media (Corning, USA). After 24 h of incubation at 37 °C and 5% CO2, cells were treated with increasing concentrations (0.001 μm to 10 μm) of doxorubicin eluted from each cement and a control doxorubicin solution. Elution samples for these tests were collected on days 1 and 5 after undergoing the aforementioned elution conditions and subsequently stored at -80 °C until testing occurred. The concentrations of these samples were quantified using HPLC and normalized to our starting concentration (10 mm). The control doxorubicin solution was prepared in PBS and maintained at 37 °C for 1 or 5 days to mimic the experimental conditions of eluted samples. After 72 h of further incubation, standard MTT assays were performed [24]. Briefly, the media containing doxorubicin was removed, and cells were incubated with MTT (5 mg/mL) in fresh DMEM for three hours. Afterwards, the media was removed, and the metabolic product of the MTT was solubilized with DMSO (Sigma-Aldrich, Saint Louis, MO, USA). Results were obtained by reading the plate at 570 nm using a Synergy H1 plate reader (Biotek, Vermont, USA) and the doxorubicin dose required to inhibit the metabolism of the cells (Inhibitory Concentration 50%, IC50) was determined using GraphPad Software (San Diego, CA, USA). Mechanical property testing The compressive strength of specimens from each group was measured through axial loading using an MTS Mini Bionix 858 loadframe with MTS Series 793™ Control Software (MTS Systems Corporation, Eden Prairie, MN, USA). Initial testing was performed on dry specimens 24 h after soaking to gain a “Day 1” baseline. Further testing was performed on PBS-soaked specimens that were stored at 37 °C at 7- and 14-days post-curing. A sample number of 10 replicates was used for each group at each time point. All compression testing was performed according to ASTM F451 standards for acrylic cements [23]. Collection of data was performed at 20 Hz and a loading rate of 20 mm/min. Axial loading was done until either 40% strain was reached, or specimen fracture occurred. Fracture was defined as a precipitous drop in load to below 90% of its peak value. Compressive strength was calculated as the failure load of each pellet divided by its cross-sectional area. The failure load was taken as either the load at the 2.0% offset from the elastic section of the stress-strain curve, the ultimate yield load, or the load at fracture, whichever occurred first. PMMA exothermicity testing To further investigate the effect of doxorubicin on PMMA, a single fresh batch of both control and doxorubicin-laden PMMA cement were made for measuring the exothermic output during curing. Each cement group was mixed until the dough stage was reached as per ASTM F451 and subsequently placed into a custom PTFE thermocouple mold with a k-type thermocouple wire [23]. The internal temperature of each cement was recorded every 5 s for 45 min using an Omega OM-PLTC Thermocouple Temperature Data Logger (Omega, Stamford, CT). The exothermicity of SBB groups was not measured, as SBB has been shown previously to undergo a non-exothermic curing process [25]. Statistical analysis For all elution and strength tests per time point, a sample size of ten was used. Paired two-tailed t-tests were employed to compare both the daily and cumulative average elution concentrations between the PMMA and SBB cements. To determine the mechanical strength deviation of doxorubicin-laden cements from their respective controls, a single-factor ANOVA was used. Sample size for each test is indicated in figure captions. All statistical calculations were performed using SPSS software (SPSS, IBM Corporation, Armonk, NY). Results Doxorubicin elution The elution profiles of doxorubicin incorporated PMMA and SBB are displayed in Fig. 2. Both cements released detectible concentrations of doxorubicin over the course of 7 days. PMMA was shown to release higher concentrations during the first 48 h, but after that time, it was not significantly different from SBB samples (p < 0.05).Fig. 2Daily average elution concentrations of doxorubicin from both PMMA and SBB specimens. Error bars indicate ± one standard deviation from the mean. n = 10 Daily average elution concentrations of doxorubicin from both PMMA and SBB specimens. Error bars indicate ± one standard deviation from the mean. n = 10 Doxorubicin efficacy testing The cell viability curves and for experimental and control doxorubicin samples against both MG63 and WI38 cells are displayed in Fig. 3. The calculated IC50 values are displayed in Table 2. The IC50 of doxorubicin eluted from SBB was shown to be non-significantly different from the control on Day 1 (p < 0.05). On the other hand, the PMMA-eluted doxorubicin had a higher IC50 and was significantly different from control and SBB for Days 1 and 5 (p < 0.05) for both cell lines.Fig. 3Cell viability (vitality) curves (dose-response curves) for control and experimental doxorubicin against both MG63 and WI38 cells at 1- and 5-days of elution collection. Day 5 SDOX concentrations were not high enough to meet assay starting conditions. Error bars indicate ± 1 standard deviation from the mean. n = 3Table 2IC50 values (µm) for control doxorubicin (DCON) and eluted doxorubicin (PDOX and SDOX) against both MG63 experimental and WI38 control cells lines n = 3MG63WI38GroupDay 1Day 5Day 1Day 5DCON0.6702.2101.9557.385PDOX5.0468.6879.1339.547SDOX0.7292.4481.508- Cell viability (vitality) curves (dose-response curves) for control and experimental doxorubicin against both MG63 and WI38 cells at 1- and 5-days of elution collection. Day 5 SDOX concentrations were not high enough to meet assay starting conditions. Error bars indicate ± 1 standard deviation from the mean. n = 3 Table 2IC50 values (µm) for control doxorubicin (DCON) and eluted doxorubicin (PDOX and SDOX) against both MG63 experimental and WI38 control cells lines n = 3MG63WI38GroupDay 1Day 5Day 1Day 5DCON0.6702.2101.9557.385PDOX5.0468.6879.1339.547SDOX0.7292.4481.508- IC50 values (µm) for control doxorubicin (DCON) and eluted doxorubicin (PDOX and SDOX) against both MG63 experimental and WI38 control cells lines n = 3 Mechanical strength The compressive strengths of all experimental groups are displayed in Fig. 4. The deviation in compressive strength over 14 days for doxorubicin-loaded specimens in relation to their respective controls is displayed in Fig. 5. The incorporation of doxorubicin into PMMA resulted in a significant decrease in strength as compared to the control for all time points (p < 0.05). No significant decrease was observed for doxorubicin-laden SBB samples (p < 0.05). All cement groups remained above 70 MPa, which is the ISO standard for cement weight-bearing applicability for orthopedic applications [26].Fig. 4Compressive strengths for all cement groups over the course of 14 days. An asterisk (*) denotes a significant difference between groups at the end of the bar (p < 0.05). Dashed line indicates 70 MPa ISO threshold n = 10Fig. 5Percentage deviation in compressive strength values for experimental groups (PDOX, SDOX) from their respective controls (PCON, SCON) over 14 days. Mean, n = 10 Compressive strengths for all cement groups over the course of 14 days. An asterisk (*) denotes a significant difference between groups at the end of the bar (p < 0.05). Dashed line indicates 70 MPa ISO threshold n = 10 Percentage deviation in compressive strength values for experimental groups (PDOX, SDOX) from their respective controls (PCON, SCON) over 14 days. Mean, n = 10 Exothermicity testing The exothermic outputs during curing of PMMA cements are displayed in Fig. 6. The doxorubicin-incorporated PMMA showed a 24.8 °C reduction in Tmax (highest temperature reached) as compared to control PMMA (67.7 vs. 92.5 °C, Table 3). In addition, the total overall exothermic output over the course of 45 min was substantially reduced for the doxorubicin-incorporated PMMA, suggesting a reduction in total bond formation. Exothermic output was not recorded for SBB groups, as SBB undergoes a non-exothermic polymerization.Fig. 6Exothermic output of each PMMA group during curing using a PTFE mold with a k-type thermocouple wireTable 3Temperature values for PMMA groups during cutting. Maximum temperature achieved during curing (Tmax) and ending temperatureGroupTmax (°C)Ending T (°C)PCON92.533.0PDOX67.726.5 Exothermic output of each PMMA group during curing using a PTFE mold with a k-type thermocouple wire Table 3Temperature values for PMMA groups during cutting. Maximum temperature achieved during curing (Tmax) and ending temperatureGroupTmax (°C)Ending T (°C)PCON92.533.0PDOX67.726.5 Temperature values for PMMA groups during cutting. Maximum temperature achieved during curing (Tmax) and ending temperature Discussion As a biomaterial often already present at the osteosarcoma or metastatic lesion resection site, bone cement could serve as a convenient carrier for local chemotherapy delivery. Our results showed that both PMMA and SBB cements were able to incorporate and release doxorubicin over the course of 7 days. However, doxorubicin released from PMMA was less efficacious than either control or SBB-released doxorubicin, suggesting alteration of the doxorubicin structure itself. These effects were not observed in doxorubicin-laden SBB cement, suggesting SBB and doxorubicin had no discernible chemical interaction. Furthermore, results from both the mechanical compression testing and exothermic curing data showed there to be a likely reduction in PMMA polymerization upon doxorubicin incorporation. A significant reduction in the mechanical strength of PMMA upon doxorubicin incorporation suggests the notion of a less complete matrix. Additionally, the reduction in total exothermic output of doxorubicin-laden PMMA during curing can be correlated to a reduction in the total enthalpy of bond formation and thus a lower extent of MMA polymerization. Our results demonstrated that doxorubicin has a hindering effect on PMMA cement polymerization similar to that of rifampin. In the 2019 paper by Funk et al., rifampin incorporation (1 g per 40 g dry cement, 1.89 total w/w%) was found to decrease the strength of PMMA cement by 65% at 24 h after mixing [20]. Even when incorporating a much smaller amount of doxorubicin (400 mg in 40 g of dry cement, 0.68 w/w%), the authors noted an 18% decrease of strength at 24 h. Several authors have studied the incorporation of doxorubicin into PMMA cement, but only two have reported on the effect of incorporation on cement strength or doxorubicin’s activity. These papers both reported results that may be considered in conflict with our findings and conclusions regarding strength reductions in doxorubicin-laden PMMA. In a 1992 study by Greco et al., the authors noted no inhibition of polymerization [27]. This result was based only on physical observation which may not have picked up on the reductions in exothermic output and strength we have noted. Likewise, Healey et al. reported only small reductions in the compressive strength (approx. 4–5%) of PMMA cement following the addition of 0.5 g of doxorubicin and 0.5 g of pamidronate with additional reduction following increased additive amounts [28]. These would be considered much lower than the reductions expected based on our results. Additionally, based on HPLC data, Healey et al. concluded that the structure of doxorubicin was not altered upon elution from PMMA, but solely from its degradation in PBS over time. However, they did not undertake bioassays to test for changes in efficacy. While we noted that control doxorubicin kept in PBS for 5 days did show reduced efficacy, we saw a significant difference in efficacy between SBB-eluted and PMMA-eluted doxorubicin on both Days 1 and 5 of viability testing. This additional control allowed us to verify the existence of PMMA’s effect on doxorubicin under two different treatments, SBB and PMMA incorporation. These results suggest that while storage in PBS at 37 °C has some degradation effect, there is also a substantial chemical effect of PMMA on doxorubicin. Hydroquinone, such as the moiety contained within doxorubicin, is known to be a radical scavenger. Therefore, it is highly likely that, akin to rifampin, doxorubicin’s hydroquinone moiety could be oxidized to either a semiquinone or quinone as it quenches free radical species during PMMA polymerization (Fig. 7). Doxorubicin belongs to the family of anthracycline drugs which includes daunorubicin, idarubicin, epirubicin, and pirarubicin. Each of these drugs contains a tetracyclic ring containing adjacent quinone-hydroquinone groups and a sugar attached by a glycosidic linkage to the ring. Therefore, it can be predicted that any of the other anthracyclines may also have a similar quenching effect on PMMA polymerization if incorporated.Fig. 7Depiction of the theorized oxidation of the hydroquinone moiety (circled) in doxorubicin by free radical species during PMMA polymerization Depiction of the theorized oxidation of the hydroquinone moiety (circled) in doxorubicin by free radical species during PMMA polymerization Members of the anthracycline family are known to be cardiotoxic which is their major dose-limited side effect. The mechanism of this toxicity has not been completely and satisfactorily clarified, but it is thought that doxorubicin and other agents in the anthracycline family damage cardiomyocytes through generation of free radicals formed during the drug’s metabolism [10, 29]. When reduced by NADH dehydrogenase in mitochondrial respiratory complex I, doxorubicin forms a semiquinone radical that can react with oxygen to form a superoxide radical. Subsequent redox cycling then results in the production of hydrogen peroxide and the hydroxyl radical [8]. It is likely that cardiomyocytes are much more sensitive to oxidative stress because of their high oxidative substrate metabolism [29]. The clinical ramifications of oxidized doxorubicin are unclear at this point; however, we have demonstrated the lower chemotherapeutic efficacy of PMMA-released doxorubicin. From our experiments thus far, we cannot determine whether this is because each doxorubicin molecule has been altered and is less effective or whether only a portion of the drug has been altered becoming ineffective, while the remainder unaltered drug is still effective. An alteration on the molecular level could potentially reduce the affinity of doxorubicin for its binding domain in topoisomerase II. There is also concern for how alterations in the molecule’s structure might affect its cardiotoxicity. It may be speculated that the creation of another quinone through oxidation could exacerbate ROS formation and thus increase the potential for doxorubicin-induced cardiotoxicity. The lack of a detectable interaction between doxorubicin and SBB is interesting and revealing in and of itself. It is noted that both heat and chemically sensitive additives can be incorporated into SBB without concern due to its non-radical polymerization and subsequently low curing temperature. On the other hand, such additives may themselves degrade or inhibit the polymerization of PMMA-based bone cements. In fact, our previous work on rifampin-laden PMMA bone cement and SBB showed polymerization attenuation in PMMA but had no effect on SBB based upon mechanical strength deviation from their non-rifampin controls [19]. Furthermore, the mechanical strength of rifampin-laden SBB was not altered. In this work, we observed no attenuation in SBB’s mechanical properties from doxorubicin incorporation. Furthermore, doxorubicin appeared to maintain its antineoplastic activity when incorporated into SBB based on our MTT assays, suggesting the doxorubicin structure remained unaltered throughout elution. Conclusion In this study, we’ve shown that both PMMA bone cement and SBB can release doxorubicin. We found that doxorubicin likely interferes with PMMA polymerization, resulting in both a reduction in mechanical strength of the resultant PMMA and a reduction in the efficacy of the eluted doxorubicin. In contrast, there was no reduction in either the mechanical strength of the SBB or the efficacy of the eluted doxorubicin. Therefore, the incorporation of doxorubicin, or other anthracyclines, into PMMA bone cement should be done only with great care and appreciation for both the potential effects the agent has on the mechanical properties of the cement and the potential alterations that PMMA cement may induce in the anthracycline’s chemical structure and efficacy. Other polymers, such as silorane-based cements, which do not proceed via radical polymerization, might make a better choice as a vehicle for this chemotherapy agent’s local delivery.